

Mark D. Girgis, M.D.

Professional Address

David Geffen School of Medicine at UCLA
10833 LeConte Ave, 72-215 CHS
Los Angeles, CA 90095
Phone: (310) 206-6889
Fax: (310) 825-9565
Email: mdgirgis@mednet.ucla.edu

EDUCATION:

WASHINGTON UNIVERSITY IN ST. LOUIS, MO B.A. in Biological Sciences	1999-2003
LOYOLA UNIVERSITY STRITCH SCHOOL OF MEDICINE M.D.	2003-2007
UNIVERSITY OF CALIFORNIA, LOS ANGELES MEDICAL CENTER Internship in General Surgery	2007-2008
Resident in General Surgery	2008-2013
Chief Resident in General Surgery	2013-2014
Research Fellow in General Surgery	2009-2011
UNIVERSITY OF PITTSBURGH MEDICAL CENTER Fellow in Complex General Surgical Oncology Expected Graduation Date: June 2016	2014 – present

LICENSURE:

California License #A108704	2009 – present
DEA license #FG3590103	2015 – present

PROFESSIONAL EXPERIENCE:

UNIVERSITY OF CALIFORNIA, LOS ANGELES MEDICAL CENTER Assistant Professor of Surgery	2016- present
UNIVERSITY OF PITTSBURGH MEDICAL CENTER Fellow in Complex General Surgical Oncology Expected Graduation Date: June 2016	2014 – 2016
UNIVERSITY OF CALIFORNIA, LOS ANGELES MEDICAL CENTER Internship in General Surgery	2007-2008
Resident in General Surgery	2008-2013
Chief Resident in General Surgery	2013-2014
Research Fellow in General Surgery	2009-2011

PROFESSIONAL ACTIVITIES:

American College of Surgeons, member	2013 – present
Longmire Society, member	2013 – present
Society of Surgical Oncology, member	2014 - present
American Society of Clinical Oncology, member	2014 – present

AWARDS AND HONORS

Administrative Chief Surgical Fellow	2015 – 2016
Overall Best Surgical Resident (UCLA)	2013 – 2014
ACS Jameson L. Chassin Professionalism in General Surgery Award Top 10 Finalist	2013 – 2014
Administrative Chief Surgical Resident	2013 – 2014
GI ASCO Merit Award	2010 – 2011
AAS Outstanding Resident Research Award	2010 – 2011
Outstanding Medical Student Teaching Award	2009 – 2011
2 nd year resident of the year	2008 – 2009

Lectures/Presentations:

- 1) Robotic Approach Mitigates the Risk of Wound Infection and Perioperative Morbidity in Obese Patients Following Pancreaticoduodenectomy, Pancreas Club, San Diego, CA, May 2016
- 2) Robotic Approach Mitigates the Risk of Wound Infection and Perioperative Morbidity in Obese Patients Following Pancreaticoduodenectomy, Americas Hepato-Pancreato-Biliary Association, Sao Paulo, Brazil, April 2016
- 3) Robotic Approaches to Surgical Oncology, Medical College of Wisconsin, Milwaukee, WI, Feb 2016
- 4) Long Term Oncologic Outcomes After Robotic Resections Are Not Inferior to Open for Pancreas Cancer, Pancreas Club, Washington D.C., May 2015
- 5) Robotic Pancreaticoduodenectomy with Portal Vein Resection and Patch Venoplasty, Americas Hepato- \ Pancreato-Biliary Association, Miami, FL, April 2015
- 6) MicroPET Imaging of an *In Vivo* Bioorthogonal Click Chemistry Reaction between a Novel Radiolabeled Probe and Nanoparticles, World Molecular Imaging Conference, San Diego, CA, Sept 2011
- 7) An Engineered Anti-CA19-9 Cys-Diabody for PET Imaging of Pancreas Cancer and Targeting of Nanoparticles, Society of Surgical Oncology, San Antonio, TX, March 2011
- 8) Targeting Pancreas Cancer Utilizing An Engineered Anti-CEA Antibody Fragment, Society of Surgical Oncology, San Antonio, TX, March 2011
- 9) Anti-CA19-9 Diabody as a PET Imaging Probe for Pancreas Cancer. (Association for Academic Surgery, Huntington Beach, CA, Feb 2011.
- 10) Low-Dose (550cGy), Single Exposure Total Body Irradiation (TBI) and Cyclophosphamide as Conditioning for Unrelated Donor (URD) Bone Marrow Transplant (BMT) Results in Consistent Donor Cell Engraftment without Fatal Regimen-Related Toxicity (RROT), American Society of Hematology, Philadelphia, PA, Nov 2001.

RESEARCH PUBLICATIONS:

RESEARCH PAPERS (PEER REVIEWED):

A: RESEARCH PAPERS- PEER REVIEWED:

1. Hallemeier C, **Girgis M**, Blum W, Brown R, Khoury H, Goodnough LT, Vij R, Devine S, Wehde M, Postma S, Lin HS, Dipersio J, Adkins D. Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants. *Biol Blood Marrow Transplant.* 2004 May;10 (5):310-9
-Duties included data collection and analysis and manuscript preparation
2. **Girgis M.**, Hallemeier C., Blum W., Brown R., Lin HS., Khoury H., Goodnough LT., Vij R., Devine S., Wehde M., Postma S., Oza A., Dipersio J., Adkins D. Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide. *Blood.* 2005 Apr 15; 105(8): 3035-41.
3. Hallemeier CL, **Girgis MD**, Blum WG, Brown RA, Khoury HJ, Devine SM, Vij R, Lin HS, DiPersio JF, Adkins DR. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide. *Biol Blood Marrow Transplant.* 2006 Jul;12(7):749-57
-Duties included data collection and analysis and manuscript preparation
4. **Girgis MD**, Olafsen T, Kenanova V, McCabe KE, Wu AM, Tomlinson JS. Anti-CA19-9 Diabody as a PET Imaging Probe for Pancreas Cancer. *J Surg Res.* 2011 Oct;170(2):169-78
5. **Girgis MD**, Olafsen T, Kenanova V, McCabe KE, Wu AM, Tomlinson JS. CA19-9 as a Potential Target for Radiolabeled Antibody-based Positron Emission Tomography of Pancreas Cancer. *Int J Mol Imag.* July 2011 (2011): 1-9
6. **Girgis MD**, Olafsen T, Kenanova V, McCabe KE, Wu AM, Tomlinson JS. Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment. *EJNMMI Res.* 2011 Nov 7;1(1):24
7. **Girgis MD**, Federman N, McCabe KE, Rochefort M, Wu AM, Nagy JO, Denny C, Tomlinson JS. An Engineered Anti-CA19-9 Cys-Diabody for PET Imaging of Pancreas Cancer and Targeting of Polymerized Liposomal Nanoparticles. *J Surg Res.* 2013 Nov;185(1):45-55
8. Rochefort MM*, **Girgis MD***, Ankeny J, Tomlinson JS. Metabolic Exploitation of the Sialic Acid Biosynthetic Pathway to Generate Site-Specifically Labeled Antibodies. *Glycobiology.* 2014 Jan;24(1):62-9 *denotes co-first authors
9. Rochefort MM, **Girgis MD**, Knowles S, Ankeny J, Bergara F, Wu AM, Tomlinson JS. A Mutated Anti CA19-9 scFv-Fc for Positron Emission Tomography of Human Pancreatic Cancer Xenografts. *Molecular Imaging and Biology.* 2014 Oct;16(5):721-9
-Hypothesis creation, study design, and primary research were performed
10. Ankeny JS†, Court CM†, Hou S, Li Q, Song M, Wu D, Chen JF, Lee T, Lin M, Sho S, Rochefort MM, **Girgis MD**, Wainberg ZA, Muthusamy VR, Watson R, Donahue TR, Hines OJ, Reber HA, Graeber TG, Tseng HR, Tomlinson JS († Denotes Co-First Authorship). Circulating Tumor Cells as an Adjunctive Biomarker for Diagnosis and Staging in Pancreatic Cancer. *British Journal of Cancer.* 2016 Jun 14; 114 (12):1367-75
-Contributed to hypothesis creation and study design

B: RESEARCH PAPERS-PEER REVIEWED (IN PRESS):

1. None

C. RESEARCH PAPERS - PEER REVIEWED (SUBMITTED)

1. None

RESEARCH PAPERS (NON-PEER REVIEWED)

D. RESEARCH PAPERS - NON-PEER REVIEWED

1. None

E. RESEARCH PAPERS - NON-PEER REVIEWED (IN PRESS)

1. None

F. RESEARCH PAPERS - NON-PEER REVIEWED (SUBMITTED)

1. None

CHAPTERS

1. None

LETTERS TO THE EDITOR

1. None

REVIEWS

1. Liu K, Wang MW, Lin WY, Phung DL, **Girgis MD**, Wu AM, Tomlinson JS, Shen C. Molecular Imaging Probe Development using Microfluidics. *Current Organic Synthesis*. 2011 Aug 8 (4): 473-487
-Duties include concept development and manuscript preparation

EDITORIALS

1. None

PAPERS IN PREPARATION (RESEARCH COMPLETED)

1. **Girgis MD**, King J, Steve J, Zenati MS, Novak S, Winters SB, Bartlett DL, Zureikat A, Zeh HJ, Hogg ME. Long Term Oncologic Outcomes After Robotic Resections Are Not Inferior to Open for Pancreas Cancer. In preparation.
2. **Girgis MD**, Zenati MS, Steve J, Zureikat A, Bartlett DB, Zeh HJ, Hogg ME. Robotic Approach Mitigates the Risk of Wound Infection and Perioperative Morbidity in Obese Patients Following Pancreaticoduodenectomy. In preparation.

ABSTRACTS

1. **Girgis M.**, Brown RA., Khoury H., Hallemeier C., Zehnbauer B., Goodnough LT., Westervelt P., Vij R., Blum W., Lin HS., Dipersio J., Adkins D. Low-Dose (550cGy), Single Exposure Total Body Irradiation (TBI) and Cyclophosphamide as Conditioning for Unrelated Donor (URD) Bone Marrow Transplant (BMT) Results in Consistent Donor Cell Engraftment without Fatal Regimen-Related Toxicity (RROT). (American Society of Hematology Annual Meeting Abstracts), Nov 2002
2. **Girgis M.**, Hallemeier C., Blum W., Brown R., Lin HS., Khoury H., Goodnough LT., Vij R., Devine S., Wehde M., Postma S., Dipersio J., Adkins D. Low-Dose (550cGy), Single Exposure Total Body Irradiation (TBI) with Cyclophosphamide as Conditioning for 99 Patients Undergoing Unrelated Donor (URD) Bone Marrow Transplant (BMT) Results in Graft Failure Rate (7.1%) Comparable to That Observed with Standard TBI-Based Regimens. (American Society of Hematology Annual Meeting Abstracts), Nov. 2002
3. Camacho PM., **Girgis M.**, Sapountzi P., Holmes E., Sinacore J. Correlations between Vitamin D, Parathyroid Hormone, Urinary Calcium Excretion, Markers of Bone Turnover and Bone Density of Patients Referred to an Osteoporosis Center. (American Society of Bone and Mineral Research Annual Meeting Abstracts), May 2005
4. **Girgis MD**, Kenanova V, Olafsen T, McCabe K, Wu A, Tomlinson JS. Radiolabeled Anti-CEA and Anti-CA19-9 as PET Imaging Probes for Pancreas Cancer. (American Society of Clinical Oncology Gastrointestinal Cancers Symposium Annual Meeting Abstracts), January 2010
5. **Girgis MD**, Kenanova V, Olafsen T, McCabe K, Wu A, Tomlinson JS. Radiolabeled Anti-CEA and Anti-CA19-9 as PET Imaging Probes for Pancreas Cancer. (Society of Surgical Oncology Annual Meeting Abstracts), March 2010
6. **Girgis MD**, McCabe K, Federman N, Wu AM, Denny C, Tomlinson JS. Targeting Cancer Using Cys-Diobody Conjugated Polymerized Liposomal Nanoparticles (PLNs). (Molecular Diagnostics in Cancer Therapeutic Development Annual Meeting Abstracts), Sept 2010
7. Lin WY, Liu K, Wang M, **Girgis MD**, McCracken M, Tomlinson JS, Wu AM, Shen CKF. Bioorthogonal ¹⁸F- labeling of Biomolecules via Inverse Electron Demand Diels-Alder Cycloaddition. (World Molecular Imaging Conference Annual Meeting Abstracts), Sept 2010
8. **Girgis MD**, Kenanova V, Olafsen T, Bergara F, McCabe K, Wu A, Tomlinson JS. An Engineered Anti-CA19-9 Cys-Diobody for PET Imaging of Pancreas Cancer and Targeting of Polymerized Liposomal Nanoparticles. (American Society of Clinical Oncology Gastrointestinal Cancers Symposium Annual Meeting Abstracts), January 2011
9. **Girgis MD**, Kenanova V, Olafsen T, McCabe K, Wu A, Tomlinson JS. Anti-CA19-9 Diobody as a PET Imaging Probe for Pancreas Cancer. (Association for Academic Surgery Annual Meeting Abstracts, Plenary Session), Feb 2011.
10. **Girgis MD**, Kenanova V, Olafsen T, Bergara F, McCabe K, Wu A, Tomlinson JS. An Engineered Anti-CA19-9 Cys-Diobody for PET Imaging of Pancreas Cancer and Targeting of Nanoparticles. (Society of Surgical Oncology Annual Meeting Abstracts), March 2011
11. **Girgis MD**, Kenanova V, Olafsen T, Bergara F, McCabe K, Wu A, Tomlinson JS. Targeting Pancreas Cancer Utilizing An Engineered Anti-CEA Antibody Fragment. (Society of Surgical Oncology Annual Meeting Abstracts), March 2011
12. **Girgis MD**, Lin WY, Hou S, Lin YY, Shen C, Tomlinson JS. MicroPET Imaging of an *In Vivo* Bioorthogonal Click Chemistry Reaction between a Novel Radiolabeled Probe and Nanoparticles. (World Molecular Imaging Conference Annual Meeting Abstracts), Sept 2011
13. Quiroz R, Ngo R, Hsu C, Chen YH, Shen CK, **Girgis MD**, Hui H, Go VL, Lin YY. Contrast-Enhanced MR Molecular Imaging Detection of Pancreatic Cancer with Anti-CA19-9 Conjugated Magnetic Nanoparticles and Rotating-Frame Spin-Locking. (World Molecular Imaging Conference Annual Meeting Abstracts), Sept 2011
14. Rochefort MM, **Girgis MD**, Knowles SM, Bergara F, Olafsen T, Tomlinson JS. An Engineered Chimeric Fc Mutated, Anti-CA19-9 scFv-Fc for Imaging Pancreas Cancer. (Society of Surgical Oncology Annual Cancer Symposium) March 2012
15. Rochefort MM, **Girgis MD**, Knowles SM, Pandol SJ, Tomlinson JS. An Engineered Chimeric, Fc Mutated, Anti-CA 19-9 scFvFc for Imaging Pancreas Cancer. (Annual Meeting of the Pancreas Club) May 2012

16. Rochefort M, **Girgis MD**, Knowles S, Tomlinson JS. An engineered chimeric, Fc mutated, Anti-CA19-9 scFv-Fc for Imaging an Orthotopic Pancreas Cancer Model. (AACR Pancreas Cancer: Progress and Challenges Annual Meeting Abstracts), July 2012
17. Ankeny JS, Hou S, OuYang H, Lin M, Song M, Rochefort MM, **Girgis MD**, Isacoff WH, Wainberg Z, Tseng HR, Tomlinson JS. Pancreatic Circulating Tumor Cells as a Diagnostic Adjunct in Pancreatic Cancer (GI-ASCO Gastrointestinal Cancers Symposium Annual Meeting Abstracts) Jan 2014
18. Ankeny JS, Hou S, Lin M, Ouyang H, Song M, Rochefort M, **Girgis MD**, Tseng HR, Tomlinson JS. NanoVelcro Technology for the Capture and Molecular Analysis of Pancreatic Circulating Tumor Cells. (Association for Academic Surgery Annual Meeting Abstracts) Feb 2015
19. **Girgis MD**, Zureikat A, Zeh HJ, Hogg ME. Robotic Pancreaticoduodenectomy with Portal Vein Resection and Patch Venoplasty. (Americas Hepato-Pancreato-Biliary Association Annual Meeting Abstracts) April 2015
20. **Girgis MD**, King J, Steve J, Zenati MS, Novak S, Winters SB, Bartlett DL, Zureikat A, Zeh HJ, Hogg ME. Long Term Oncologic Outcomes After Robotic Resections Are Not Inferior to Open for Pancreas Cancer. (Pancreas Club Annual Meeting Abstracts) May 2015
21. **Girgis MD**, Zenati MS, Steve J, Zureikat A, Bartlett DB, Zeh HJ, Hogg ME. Robotic Approach Mitigates the Risk of Wound Infection and Perioperative Morbidity in Obese Patients Following Pancreaticoduodenectomy. (Americas Hepato-Pancreato-Biliary Association Annual Meeting Abstracts). April 2016
22. **Girgis MD**, Zenati MS, Steve J, Zureikat A, Bartlett DB, Zeh HJ, Hogg ME. Robotic Approach Mitigates the Risk of Wound Infection and Perioperative Morbidity in Obese Patients Following Pancreaticoduodenectomy. (Pancreas Club Annual Meeting Abstracts). May 2016